Tempest Therapeutics (TPST) catalysts

Upcoming FDA decisions and readouts we track for Tempest Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Tempest Therapeutics (TPST, listed on Nasdaq). It concerns TPST-4003 (Myasthenia gravis / multiple sclerosis (CD7 in vivo CAR-T)).

First on the list: the Phase 1 readout for TPST-4003 (Myasthenia gravis / multiple sclerosis (CD7 in vivo CAR-T)), guided by the company to H1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: TPST
Next catalyst: H1 2027
Type: Phase 1 readout
Listed options: No

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Tempest Therapeutics TPST · Nasdaq	TPST-4003	Myasthenia gravis / multiple sclerosis (CD7 in vivo CAR-T)	H1 2027 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	No
Notes — Filing states "initial clinical data expected in the first half of 2027," with first patient dosing in Q4 2026. Source: 8-K exhibit 99.1, filed 13 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Cartesian Therapeutics (RNAC)Myasthenia gravis (mRNA CAR-T); Myositis; Juvenile dermatomyositis (paediatric); Myasthenia gravis
Roivant Sciences (ROIV)Non-infectious uveitis; Cutaneous lupus erythematosus; Pulmonary hypertension with interstitial lung disease; Difficult-to-treat rheumatoid arthritis; Graves’ d
Sana Biotechnology (SANA)Non-Hodgkin lymphoma (in vivo CAR-T)
Allogene Therapeutics (ALLO)Autoimmune disease (allogeneic CD19/CD70 CAR-T); First-line large B-cell lymphoma consolidation
Caribou Biosciences (CRBU)Relapsed/refractory multiple myeloma (allogeneic BCMA CAR-T)
Kyverna Therapeutics (KYTX)Stiff person syndrome; Progressive multiple sclerosis